Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 14/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7378828 | 0.86 | ADAMTS4 (0.59) | KMT2ANLRP3FBP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL7456085 | 0.85 | ADAMTS4 (0.57) | KMT2ANLRP3FBP1ALDH1A1MAPT | |
| SCHEMBL7382300 | 0.84 | NLRP3 (0.48) | KMT2ANLRP3FBP1ALDH1A1MAPT | |
| SCHEMBL3687103 | 0.82 | ADAMTS4 (0.61) | ALDH1A1HPGD | |
| SCHEMBL791357 | 0.82 | ADAMTS4 (0.61) | ALDH1A1HPGD | |
| SCHEMBL1903552 | 0.81 | SLC1A3 (0.56) | ALDH1A1HPGD | |
| SCHEMBL171036 | 0.80 | KMT2A (0.61) | KMT2ANLRP3FBP1ALDH1A1MAPT | |
| SCHEMBL7371173 | 0.78 | SLC1A3 (0.59) | KMT2ANLRP3ALDH1A1MAPT | |
| SCHEMBL27714135 | 0.78 | FBP1 (0.61) | KMT2ANLRP3FBP1ALDH1A1MAPT | |
| SCHEMBL28327825 | 0.76 | NLRP3 (0.45) | KMT2ANLRP3FBP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011051671-A1 | AMINOPYRIDINE DERIVATIVES AS KALLIKREIN INHIBITORS | VANTIA LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| EP-1334100-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1333829-A1 | TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002040469-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040022-A1 | TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONIST | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | KMT2A 4282/4885NLRP3 4131/4885FBP1 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.